Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Kazuhiro Toyoda Last modified date:2021.09.24

Assistant Professor / Center for the Study of Global Infection / Kyushu University Hospital


Papers
1. Kutsuna S, Asai Y, Yamamoto K, Shirano M, Konishi K, Asaoka T, Yamato M, Katsuragi Y, Yamamoto Y, Sahara T, Tamiya A, Nakamura-Uchiyama F, Sakamoto N, Kosaka A, Washino T, Hase R, Mito H, Kurita T, Shinohara K, Shimizu T, Kodama F, Nagasaka A, Ogawa T, Kasahara K, Yoshimura Y, Tachikawa N, Yokota K, Yuka Murai NS, Sakamaki I, Hasegawa C, Yoshimi Y, Toyoda K, Mitsuhashi T, Ohmagari N., Epidemiological trends of imported infectious diseases in Japan: Analysis of imported 2-year infectious disease registry data., J Infect Chemother, 2021 Apr;27(4):632-638, 2021.04.
2. Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K., Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination., Aliment Pharmacol Ther , 2020 Sep;52(5):866-876., 2020.09.
3. Mitsumoto-Kaseida F, Murata M, Takayama K, Toyoda K, Ogawa E, Furusyo N, Hayashi J., Prevalence and Characteristics of Occult Hepatitis B Virus Infection in Japanese Human Immunodeficiency Virus-Infected Patients., J Infect Chemother, Jan;26(1):28-32. doi: 10.1016/j.jiac.2019.06.003. Epub 2019 Jul 3., 2020.01.
4. Kakimoto M, Murata M, Mitsumoto-Kaseida F, Ogawa E, Matsumoto Y, Kusaga A, Toyoda K, Hayashi T, Ura K, Kanno K, Furusyo N, Tazuma S., Toxocariasis Suspected of having Infiltrated Directly from the Liver to the Lung through the Diaphragm., Intern Med, internalmedicine.2716-19., 2019.01.
5. Ohta A, Furusyo N, Kishihara Y, Eiraku K, Murata M, Kainuma M, Toyoda K, Ogawa E, Hayashi T, Koga T., Secondary Syphilis with Pulmonary Involvement., Intern Med, Jan 1;57(1):121-126., 2018.01.
6. Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K., Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV., Liver Int, Jan;38(1):76-83., 2018.01.
7. Mitsumoto-Kaseida F, Murata M, Toyoda K, Morokuma Y, Kiyosuke M, Kang D, Furusyo N., Clinical and pathogenic features of SCCmec type II and IV methicillin-resistant Staphylococcus aureus in Japan., J Infect Chemother, Feb;23(2):90-95, 2017.02.
8. Ogawa E, Furusyo N, Murata M, Shimizu M, Toyoda K, Hotta T, Uchiumi T, Hayashi J., Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy., Antivir Ther, 2017;22(1):61-70., 2017.02.
9. Shimizu M, Furusyo N, Tanaka Y, Kato Y, Mitsumoto-Kaseida F, Takayama K, Ura K, Hiramine S, Hayashi T, Ikezaki H, Ihara T, Mukae H, Ogawa E, Toyoda K, Kainuma M, Murata M, Hayashi J, The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS)., Int Urol Nephrol, 2016.03.
10. Ikezaki H, Furusyo N, Hiramine S, Ura K, Mitsumoto-Kaseida F, Takayama K, Shimizu M, Toyoda K, Ogawa E, Kainuma M, Murata M, Hayashi J, Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study., Arch Virol, 161(3):641-8., 2016.03.
11. Ogawa E, Furusyo N, Murata M, Hayashi T, Shimizu M, Mukae H, Toyoda K, Hotta T, Uchiumi T, Hayashi J, Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy., Antiviral Res, 126:35-42., 2016.02.
12. Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, Toyoda K, Murata M, Hayashi J, Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C., 43(1):114-24., 2016.01.
13. Mitsumoto F, Murata M, Ura K, Takayama K, Hiramine S, Shimizu M, Toyoda K, Ogawa E, Furusyo N, Hayashi J, The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients., J Infect Chemother, 2015.04.
14. Shimizu M, Furusyo N, Mitsumoto F, Takayama K, Ura K, Hiramine S, Ikezaki H, Ihara T, Mukae H, Ogawa E, Toyoda K, Kainuma M, Murata M, Hayashi J, Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS)., Atherosclerosis, 2015.02.
15. Shimizu M, Furusyo N, Ikezaki H, Ogawa E, Hayashi T, Ihara T, Harada Y, Toyoda K, Murata M, Hayashi J, Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B., World J Gastroenterol, 2015.02.
16. Kainuma M, Furusyo N, Ando S, Mukae H, Ogawa E, Toyoda K, Murata M, Hayashi J, Nocturnal difference in the ultra low frequency band of heart rate variability in patients stratified by Kampo medicine prescription., Circ J, 2014.07.
17. Ogawa E, Furusyo N, Shimizu M, Ihara T, Hayashi T, Harada Y, Toyoda K, Murata M, Hayashi J, Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C., Antivir Ther, 2014.06.
18. Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J, A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy., J Infect Chemother, 2014.03.
19. Furusyo N, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J, Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response., J Antimicrob Chemother, 2014.02.
20. Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Okada K, Kainuma M, Kajiwara E, Takahashi K, Satoh T, Hayashi J, Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia., J Viral Hepat., 2013.12.
21. Furusyo N, Ihata T, Hayashi T, Ikezaki H, Toyoda K, Ogawa E, Okada K, Kainuma M, Murata M, Hayashi J, The serum undercarboxylated osteocalcin level and the diet of a Japanese population: results from the Kyushu and Okinawa Population Study (KOPS)., Endocrine., 43, 3, 635-642, 2013.08.
22. Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J, Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays., Antiviral Res., 99, 2, 119-124, 2013.08.
23. Ihara T, Furusyo N, Hayashi T, Toyoda K, Murata M, Hayashi J, A population-based epidemiological survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS)., Arch Virol., 2013.06.
24. Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, Ikezaki H, Hiramine S, Mukae H, Toyoda K, Taniai H, Okada K, Kainuma M, Kajiwara E, Hayashi J, Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial., J Hepatol. , 57, 6, 1186-1192, 2012.12.
25. Ogawa E, Furusyo N, Murata M, Ikezaki H, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayash J, Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1., J Hepatol., 57, 3, 534-540, 2012.09.
26. Toyoda K, Furusyo N, Ihara T, Ikezaki H, Urita Y, Hayashi J, Serum pepsinogen and Helicobacter pylori infection-a Japanese population study., Eur J Clin Microbiol Infect Dis, 31, 9, 2117-2124, 2012.09.
27. Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ogawa E, Toyoda K, Taniai H, Kainuma M, Murata M, Hayashi J, Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C., J Infect Chemother. , 2011.12.
28. Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M, Hayashi J, Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog., Hepatol Res., 41, 12, 1178-1188, 2011.12.
29. Furusyo N, Walaa AH, Eiraku K, Toyoda K, Ogawa E, Ikezaki H, Ihara T, Hayashi T, Kainuma M, Murata M, Hayashi J, Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients., Gut Liver., 5, 4, 447-453, 2011.12.
30. Furusyo N, Murata M, Ogawa E, Toyoda K, Ihara T, Ikezaki H, Hayashi T, Koga T, Kainuma M, Hayashi J, Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response., J Antimicrob Chemother., 66, 5, 1127-1139, 2011.05.
31. Murata M, Furusyo N, Unnno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J, Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients., World J Gastroenterol., 17, 24, 2945-2952, 2011.01.
32. Toyoda K, Furusyo N, Takeoka H, Murata M, Sawayama Y, Hayashi J, Epidemiological study of hepatitis E virus infection in the general population of Okinawa, Kyushu, Japan.
, J Gastroenterol Hepatol, 23, 12, 1885-1890, 2008.12.